Barclays’s Cardiol Therapeutics CRDL Stock Holding History

Barclays’s Portfolio CRDL Stock Details CRDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$318	Buy	300 +100	+50%	+$127	﹤0.01%	5060
2026 Q1	$270	Buy	+200	New	+$205	﹤0.01%	4943

Other funds holding CRDL

MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Integrity Alliance Urbandale, Iowa $3.2B AUM 23.28% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Barclays's CRDL Position: Q2 2026 in Review

Barclays increased its Cardiol Therapeutics (CRDL) stake by 50% in Q2 2026, buying an estimated $127 and bringing the position to 300 shares worth $318. The position accounts for ﹤0.01% of the portfolio, ranked #5060.

Barclays first reported a position in CRDL in Q1 2026 and has held it in 2 quarters since. 52 funds tracked by Wall St. Rank hold CRDL as of Q2 2026.

Barclays held 300 shares of Cardiol Therapeutics worth $318 as of Q2 2026.
Barclays bought 100 Cardiol Therapeutics shares in Q2 2026, an estimated $127.
Cardiol Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5060 holding.
Barclays first reported a position in Cardiol Therapeutics in Q1 2026 and has held it in 2 quarters since.
52 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.